Our mission
We strive to develop innovative therapeutics, to eliminate cancers, and prevent recurrence.
We aim to provide better and more accessible treatment options to diverse patient populations around the world.
We fight every day because we know patients do too.

Confront Challenging Conditions

Maximize Benefit of Local and Regional Delivery

Patients First

Streamlined Solution-Focused Research and Development
PRV Platform Technology
Transforming innovation to hope through action.
The PRV™ platform enables targeted therapy while avoiding systemic toxicity to provide a safer, less invasive alternative to currently available treatments”
The PRV™ system is available in multiple dosage forms. Formulations include topical and intraoperatively administered patches, hydrogels, intratumral injectables.
The lead indication for PRV111 is head and neck cancer. Other indications for PRV products are:
- Carcinoma in situ
- Lung Cancer
- Colorectal Cancer
- Penile Cancer
- Esophagus Cancer
- Cervical/Vaginal Cancer/Vulvar
- Anal Cancer
- Ocular Squamous Cell Carcinoma
PRV111 stabilizes drug compounds and using polymer technology delivers them locoregionally to maximize potency and minimize toxicity.
The PRV system is currently used for locoregional treatment of cancerous tumors and precancerous lesions of the oral cavity. Additional formulations and treatment strategies comprising compounds for other cancers and indications outside of oncology are under development, with promising results.
Pipeline
The lead indication of the PRV System is oral cancer, followed by oral carcinoma in situ and intra-operative chemotherapy cancers. Privo’s Phase II clinical study on oral cancer has successfully completed meeting all of its primary and secondary endpoints. Privo oral carcinoma in situ is in phase 3

PRV111 - Topical chemotherapy
Phase 3 clinical trial
Head and neck squamous cell carcinoma
• Incidence in the US: ~53,000
• Prevalence: ~370,300
• No safe, effective neoadjuvant treatment exists

PRV211- Pivotal Stage Surgical Product
Intraoperative chemotherapy & Immunomodulation in solid tumors
• ~4,000,000 cancer surgeries in the US
• Prevalence: ~1,806,590
• No safe, effective intraoperative treatment exists
Recognition
Privo is excited to work closely with its collaborators at the FDA, the NCI and the NIDCR.
Privo Technologies has received over $11.5M in nondilutive funding from these institutions in support of its product development and clinical trial.



News
Privo Technologies, Inc. Receives IRB Approval for PRV211- Intraoperative Chemotherapy Treatment for Solid Tumors
'Peter Goldberg'2022-12-06T02:37:14+00:00Privo Technologies, Inc. is pleased to announce that it...
Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer
'Peter Goldberg'2022-12-06T02:12:20+00:00PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the...
Forbes Article “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems”
'Peter Goldberg'2022-09-08T16:03:24+00:00Privo is excited to share the recent Forbes article...